Enliven Therapeutics, Inc. Profile Avatar - Palmy Investing

Enliven Therapeutics, Inc.

Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its pipeline of small molecule kinase inhibitors include ELVN-001, which is being …

Biotechnology
US, Boulder [HQ]
Strategy & Leadership

Officers & BofD Beta

  • Form 3/4/5
  • Proxy DEF-14A

Total Compensation

- No data, only available if we have DEF 14A compensations in place -
Officers
Name & Position Research Last Appearance
- No data available -
Board of Directors (BofD)
Name & Position Research Last Appearance
- No data available -
End of ELVN's Analysis
CIK: 1672619 CUSIP: 29337E102 ISIN: US29337E1029 LEI: - UEI: -
Secondary Listings
ELVN has no secondary listings inside our databases.